Thought Leadership

Latest Report


Vantage Pharma, Biotech & Medtech Half-Year Review 2018

Report Highlights Big biotech and big pharma stocks were largely shunned by investors over the first half of the year Demand for new biotech issues shows no sign of flagging, with a record $3.5bn raised in IPOs across western stock exchanges in the first half of 2018 At the half year point 2018 is shaping up to have the lowest spend on medical…

Report library


EvaluatePharma Orphan Drug Report 2018

Report Highlights Worldwide orphan drug sales are forecasted to grow at a CAGR of 11% from 2018-2024 The mean price of the top 100 USA orphan drugs is expected to…


EP Vantage 2018 Preview

Report Highlights M&A activity expected to climb after slow 2017 – US tax reform a deciding factor for big deals Another big year predicted for venture financing…